

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. – 4. **(canceled)**

5. **(previously presented)** An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:8.

6. – 8. **(canceled)**

9. **(previously presented)** An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:7.

10. **(currently amended)** An isolated nucleic acid molecule ~~that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:7~~ comprising a nucleotide sequence encoding a polypeptide comprising an amino acid sequence having one or more conservative substitutions to SEQ ID NO: 8 or a complement of said nucleotide sequence.

11. **(canceled)**

12. **(previously presented)** A vector comprising the nucleic acid molecule of claim 5.

13. **(original)** The vector of claim 12, further comprising a promoter operably linked to said nucleic acid molecule.

14. **(previously presented)** An isolated host cell comprising the vector of claim 12.

15. – 29. **(canceled)**

30. **(previously presented)** A composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically acceptable carrier.

31. – 32. (canceled)

33. (previously presented) A kit comprising in one or more containers, the composition of claim 30.

34. – 43. (canceled)

44. (previously presented) An isolated nucleic acid molecule comprising nucleotides 38-1717 of SEQ ID NO:7.

45. (previously presented) A composition comprising the nucleic acid molecule of claim 44 and a pharmaceutically acceptable carrier.

46. (previously presented) A kit comprising in one or more containers, the composition of claim 45.

47. –52. (canceled)